Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bubs Australia gets permanent FDA nod for infant formula sales in US, shares jump

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

opportunities

◆ Sectors

Foodtech

◆ Geography

United States

◆ Source

Read at wtvbam.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

Bubs Australia received permanent FDA approval to sell three infant formula products in the US, significantly boosting its share price and positioning it among a select group of international suppliers in the US infant formula market.

This Wire brief sits within Fusion42's coverage of Foodtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You just won a rare FDA green light that cuts through complex US infant formula rules. Now’s the moment to push into private label deals and lock down your US foothold before competitors catch up.

◆ Coverage

2 sources · 7 Sep 2026

◆ Related on Wire

◆ Topics

Foodtechfda-approvalinfant-formulaus-marketaustraliaregulatory-shift